Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The increased incidence of endometrial carcinoma in Slovenia from 1961 to 1970 is presented, as well as the five-year survival of patients treated from 1946 to 1949 and from 1965 to 1972. A retrograde analysis is made of 288 patients, of the structure of their carcinomatous stages, their age, mode of treatment, and their survival in relation to the kind of treatment, the development of the cancer, its histological structure, and the magnitude of changes in regional lymph nodes. Novak's merit for the use of the so-called old Wertheim in the surgery of endometrial carcinoma is particularly pointed out.
 ...
PMID:[Results of the treatment of endometrial carcinoma (author's transl)]. 75 27

Due to adverse publicity alleging an increased risk of endometrial cancer with estrogen therapy, a prospective study was begun in 1976 to determine the incidence of this disease in postmenopausal women. During 5,025 patient-years of observation in 1976-1977, 6 adenocarcinomas of the endometrium were diagnosed for an incidence of 1.2:1,000 postmenopausal women per year. No endometrial malignancies were detected in 2,552 patient years of therapy with estrogens and progestogens. In 1,028 patient-years of observation where estrogens only was the therapy, there were 3 endometrial cancers for an incidence of 2.9:1,000. Adenocarcinoma of the endometrium was found in 2 of the untreated group, which gave an incidence of 3.0:1,000. The sixth endometrial cancer occurred in a patient using estrogen vaginal cream. During this same period, 139 perimenopausal and postmenopausal women were treated with progestogens for endometrial hyperplasia. The hyperplasia was reversed to normal endometrium in 133 patients (95.7%). Hyperplasia is a precancerous lesion and should be treated with either progestogens or hysterectomy. All postmenopausal women with a uterus should be given the Progestogen Challenge Test and the progestogen continued each month as long as bleeding follows. These methods will prevent most endometrial cancers.
 ...
PMID:The prevention of endometrial cancer in postmenopausal women with progestogens. 75 56

There is increasing epidemiological evidence that nutrition plays a dominant role in the pathogenesis of several types of human cancers. There is considerable epidemiological evidence showing that alcoholism in part because of associated nutritional deficiencies, significantly increases the risk of smokers for cancer of the alimentary tract. There is also some suggestion that nutritional deficiencies may relate to cancers of the stomach, cervix, and thyroid. Of particular importance, and based on relatively new concepts, are data indicating that overnutrition significantly affects the development of certain cancers, including cancers of the colon and pancreas, kidney, breast, ovary endometrium, and prostate. Except for cancer of the endometrium, and kidney cancer in women, there is no significant relationship to obesity. Rather, the evidence suggests both epidemiologically and experimentally that the etiological factors relate to a high intake of fats and possibly other variables associated with high fat intake. While we are investigating the mechanistic nature of the epidemiological and experimental observations, the question that needs to be asked is whether it is not prudent for us to associate ourselves with the recommendation of our colleagues in the cardiovascular disease field who call on both individuals and the food industry to practice a "Prudent Diet," i.e., one that is lower in total calories, total fat, saturated fats and cholesterol than is the present American diet.
 ...
PMID:Nutrition and cancer. 77 Feb 4

Reports in the lay press that exogenous estrogens cause endometrial cancer are unjustified with the present evidence. Mortality from endometrial cancer has not increased in the U.S. in recent years. Endometrial cancer accounts for only 1.38% of all female cancer deaths. The incidence in the U.S. has not increased since estrogen therapy has been more widely used. The acquisition of an unbiased control group is the prime requirement if valid conclusions are to be made. 1 of the most difficult problems in a retrospective study of endometrial cancer is identification of a group of women who have undergone diagnostic uterine curettage or biopsy or hysterectomy. Exclusion from the comparison group of women who have had a hysterectomy excludes a large number who would have had an opportunity for estrogen replacement therapy following the menopause. An association between 2 factors does not prove cause. It is to be hoped that fear of endometrial cancer from exogenous estrogen therapy will turn out to be a false alarm when better retrospective studies are reported or when material from the studies reported to date is reviewed further. Meantime caution is indicated. Cyclic administration of estrogens in small doses for the shortest practical time is advised. Periodic examinations, Papanicolaou smears, and frequent evaluation of the patient's symptoms are recommended. There are definite and established benefits of estrogen therapy as well as risks.
 ...
PMID:Exogenous estrogens and endometrial cancer. 77 18

Ten percent of all patients with endometrial carcinoma have Stage III disease at the time of presentation. The management, the features of their disease, and their prognosis are quite different than those of patients with Stage I disease. This report is based on 37 patients with Stage III carcinomas. For their treatment, a program of definitive radiation therapy was applied. Eleven patients had a prior total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO). On the basis of the tumor extension, three main patterns were identified: 1) downward into the vagina or the vagina and the cervix; 2) lateral into the parametrium and the pelvic wall; and 3) to the ovaries. This classification carries therapeutic and prognostic significance. Ovarian extension has the best prognosis when treated by TAH and BSO followed by postoperative radiotherapy. Extension to the vagina or to the vagina and the cervix can be treated successfully by a combination of external beam and local radium placements. Patients with pelvic wall extension have the poorest prognosis. They comprise maore than 50% of all cases with Stage III tumors and have exhibited persistent or recurrent disease even when treated at high dose levels. The cumulative survival rates for the entire stage were 50% at the end of the first year, 32% at the end of the second year, and 25% at the end of the fifth year.
Cancer 1976 Oct
PMID:The management of stage III carcinoma of the endometrium. 82 19

Women under 40 years of age rarely develop carcinoma of the endometrium, this age group comprising less than 3% of all cases in most large series. The Registry for Endometrial Carcinoma in Young Women Taking Oral Contraceptive Agents has recorded and studied 30 cases in women under 40 with a history of oral contraceptive administration, and these are compared with 25 cases in the same age group which were accessioned at the Armed Forces Institute of Pathology prior to the era during which these agents have been available, and with series reported in the literature totaling 137 cases with no contraceptive history. In the first group, special attention is paid to the 20 women who received sequential agents exclusively or predominantly, since the association with these agents (primarily Oracon) is much higher than would be expected from the fact that less that 10% of oral contraceptives used in this country are of the sequential type. An analysis of the three groups reveals a similar incidence of the various histologic types (primarily well differentiated tumors with a relatively favorable prognosis), the only difference being the presence of secretory features in 14 of 29 oral contraceptive users vs. only two of 25 women not taking these agents. Clinical and pathologic staging were also predominantly favorable, and comparable in all groups. There were, however, notably higher incidences of nulliparity, obesity, and sclerocystic ovaries--all features traditionally associated with endometrial carcinoma--in the patients not receiving oral contraceptives or receiving combined agents, suggesting that the group receiving sequentials may not represent the same constitutionally predisposed population. Only three of 55 women among our personally reviewed cases have thus far died of cancer (one in the contraceptive group and two in the non-user group) and all three of these had poorly differentiated tumors with myometrial invasion. The excellent prognosis for most patients in this age group is thus confirmed.
Cancer 1977 Feb
PMID:Endometrial carcinoma in women under 40 years of age: comparison of cases in oral contraceptive users and non-users. 83 41

Of 218 patients with early endometrial cancer treated with planned pre-hysterectomy intracavitary irradiation, 105 were operated 6 weeks after the completion of radiation therapy in the traditional fashion. A group of 113 patients, similar as to stage and differentiation of their disease, were operated on within 48 hours of the removal of the radiation sources. More than 90% of both groups were cured, indicating the lack of benefit from the traditional delayed hysterectomy sequence.
Cancer 1977 Feb
PMID:Forty years' evolution in the management of patients with endometrial carcinoma. 83 44

Histologic findings from 1,038 endometrial curettages performed for abnormal bleeding in patients 50 years old and over are presented. These findings were analyzed and compared according to the age of the patients. The overall malignancy rate was 22.7%. Endometrial carcinoma was the most common malignancy. The possibility of a malignant tumor increases with age. Atrophic endometrium was the cause of post-menopausal bleeding in 33.2% of the patients and adenomatous or adenocystic hyperplasia in 27.0%.
 ...
PMID:Genital bleeding in women aged 50 and over. 84 63

It is the committee's opinion that estrogens may become a promotional agent in the development of endometrial cancer in a small percentage of patients receiving estrogens. Since it appears that within the next few years 50% of all women by the age of 50 will have had a hysterectomy, and the disease occurs at an average age of 60 years, many women will have been removed from risk and few women's years of life may be lost. The risk is further reduced by the fact that early discovery of cancer of the endometrium has a cure rate of approximately 95%. Physicians administering estrogens should observe their patients carefully and perform curettage promptly for abnormal bleeding. More sophisticated methods of assessing the postmenopausal uterus are needed. Although the risk of estrogen users developing cancer of the breast has not been conclusively determined, patients with areas of thickening and nodularities in the breast should not receive estrogens. Women with sizable cysts should not receive any estrogenic hormone, and special consideration should be given in cases with close family histories of breast cancer. The most important factors are careful physical examination made by the patient and her physician at intervals of 6 months to 1 year and mammography when indicated.
 ...
PMID:Do estrogens cause cancer? 84 91

A series of 118 cases of adenoepidermoid carcinoma and adenosquamous tumors of the uterus is presented. The results indicate that cervical tumors are frequently occult and are often not diagnosed until late in the course of the disease. Stage for stage, the five-year survival rate is poorer than the usual results for cervical malignancy. Endometrial tumors also had a poor five-year survival rate, with a high incidence of myometrial extension. The incidence of myometrial invasion and survival figures were similar to those for poorly differentiated endometrial cancer.
 ...
PMID:Adenoepidermoid and adenosquamous carcinoma of the uterus. A clinicopathologic study of 118 cases. 85 Nov 56


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>